Archive · 12 Aug 2025
Weight Loss Drugs and Eye Health: New Study Findings
GLP-1 drugs, which help with diabetes and weight loss, might have some effects on your eyes.
Studies show that these drugs could slightly raise the chance of certain eye problems, like diabetic retinopathy and NAION.
The good news is these drugs may also lower the chances of serious eye complications.
It's important to know about these risks, and people with existing eye issues should get their eyes checked regularly.
Doctors recommend patients should be aware of these risks when taking the drug, and if needed, work with their eye doctors.
Studies link GLP-1 drugs, like semaglutide and tirzepatide, to increased risk of certain eye conditions.
The risk of diabetic retinopathy and NAION was found higher in those taking GLP-1 medicines.
GLP-1 medicines were linked to a lower rate of sight-threatening complications and need for treatment.
The European Medicines Agency notes NAION is a rare adverse reaction, affecting about 1 in 10,000.
Researchers advise patients be informed and undergo ophthalmic monitoring if they have retinopathy.
- Who
- Patients with Type 2 diabetes taking GLP-1 medicines and those with diabetic retinopathy.
- What
- GLP-1 drugs, like semaglutide and tirzepatide, may increase the risk of some eye conditions.
- When
- Studies were conducted recently over a two-year follow-up period.
- Where
- Studies were conducted internationally.
- Why
- To verify concerns about diabetic retinopathy raised during initial trials of semaglutide and to understand the impact of the medicine on the eye.
Potential Risks
Potential Benefits
Eye Health vs. Overall Health
Potential Risks
GLP-1 drugs are associated with an increased risk of diabetic retinopathy and NAION.
Potential Benefits
GLP-1 medicines are transformative in diabetes and obesity management and can lead to heart, kidney, and liver health benefits.
- Drug Examples
- Semaglutide, Tirzepatide, Dulaglutide, Liraglutide
- Eye Conditions Studied
- Diabetic Retinopathy, NAION
- NAION Risk (EMA)
- Extremely rare; ~1 in 10,000
- Recommendation
- Patients should be informed and monitored for eye conditions.
